Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's no wonder Wall Street investment banks are telling anyone who will listen that sales of anti-obesity drugs could soar.Last year, Morgan Stanley said the global market for obesity drugs could increase more than 15-fold to reach $144 billion by 2030. Treatments from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) dominate the market now, but the glucose-like peptide-1 (GLP-1) receptor agonists they market require weekly injections.The needles used to inject Novo Nordisk's and Eli Lilly's GLP-1 drugs are relatively slim, but there are still plenty of folks who won't go near them. To better serve this group, Eli Lilly and its peers are developing GLP-1 drugs that can be swallowed instead of injected.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool